(Updated - June 9, 2015 7:05 AM EDT)

Regeneron (NASDAQ: REGN) trading halted with news pending.

UPDATE - The halt comes ahead of the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which will review Regeneron and Sanofi's PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody, Praluent.

BMO Capital recently commented on the matter here, and RBC Capital commented here.

FDA Trading Halts

Regeneron (REGN) Resumes Trading Up 1%June 9, 2015 6:50 PM Regeneron (REGN) to Resume Trading at 6:50PM ETJune 9, 2015 6:36 PM Regeneron (REGN) Confirms FDA Panel Backing of PraluentJune 9, 2015 6:34 PM Regeneron (REGN) PRALUENT Briefing Docs Positive But Risk to Labeling for Statin Intolerance, BMO Capital SaysJune 8, 2015 7:03 AM FDA Breifing Documents for Regeneron's (REGN) Praluent 'Read Well,' Says RBC CapitalJune 5, 2015 9:35 AM